3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Veristat will attend the upcoming ASH Annual Meeting 2018 taking place in San Diego, California from Dec 1-4, 2018, the premier event in malignant and non-malignant hematology.
Veristat has guided clients through the conduct of more than 100 clinical trials and nearly 20 regulatory agency submissions for blood diseases. Our experience spans clinical development consulting, full clinical trial oversight, and regulatory submission preparation for rare genetic blood disorders and autoimmune blood diseases, as well as blood cancers.
Our experts, John Balser, and Barbara Balser, as well as Cindy Henderson and Shaheen Limbada, will be attending.
Schedule A Meeting:
Schedule a time to speak with Veristat at the event on how we can put our oncology clinical trial and regulatory submission experience to work for you. Fill out the form on the right.
Explore Our Key Related Services:
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...